Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) Income towards Parent Company: 2020-2024

Historic Income towards Parent Company for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to -$130.3 million.

  • Tango Therapeutics' Income towards Parent Company rose 154.46% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.5 million, marking a year-over-year increase of 18.57%. This contributed to the annual value of -$130.3 million for FY2024, which is 28.07% down from last year.
  • Per Tango Therapeutics' latest filing, its Income towards Parent Company stood at -$130.3 million for FY2024, which was down 28.07% from -$101.7 million recorded in FY2023.
  • Tango Therapeutics' 5-year Income towards Parent Company high stood at -$52.0 million for FY2020, and its period low was -$130.3 million during FY2024.
  • In the last 3 years, Tango Therapeutics' Income towards Parent Company had a median value of -$108.2 million in 2022 and averaged -$113.4 million.
  • Per our database at Business Quant, Tango Therapeutics' Income towards Parent Company plummeted by 85.81% in 2022 and then climbed by 5.99% in 2023.
  • Over the past 5 years, Tango Therapeutics' Income towards Parent Company (Yearly) stood at -$52.0 million in 2020, then declined by 12.07% to -$58.2 million in 2021, then tumbled by 85.81% to -$108.2 million in 2022, then grew by 5.99% to -$101.7 million in 2023, then dropped by 28.07% to -$130.3 million in 2024.